Risk factors in a patient with fungemia caused by fluconazole-resistant Candida albicans

• Autorzy: Ayse Kaya , Muhterem Yucel , Istemi Yucel
• Języki publikacji: EN

Abstrakty

EN

Blood stream infections due to Candida species are becoming increasingly important causes of morbidity and mortality in hospitalized patients. Risk factors that predispose patients to developing invasive Candida infections have been documented as, iatrogenic and/or nosocomial conditions and immunosuppression. In the present report, we want to emphasize the risk factors that predispose individuals to the development of candidemia, particularly those that are relevant to our patient. We describe a female patient with diabetes mellitus who had been receiving glucocorticoids for 20 years as replacement therapy for hypopituitarism resulting from hypophysis adenoma surgery. The patient received antibiotic therapy for recurrent wound infections and was hospitalized for a long time, including a period in the intensive care unit and instrumented. The patient eventually succumbed to fungemia caused by a fluconazole-resistant strain of C. albicans strain.

Słowa kluczowe

EN

Fungemia; Risk factors; C. albicans; Fluconazole resistance; Diabetes mellitus; Glucocorticoid

• Czasopismo: Open Medicine
• Rocznik: 2008
• Tom: 3
• Numer: 3
• Strony: 358-360

Daty

wydano

2008-09-01

online

2008-07-10

Twórcy

autor

Ayse Kaya

• Department of Microbiology and Clinical Microbiology, Medical Faculty, Duzce University, Duzce, Turkey,

autor

Muhterem Yucel

• Department of Microbiology and Clinical Microbiology, Medical Faculty, Duzce University, Duzce, Turkey

autor

Istemi Yucel

• Department of Orthopaedics and Traumatology, Medical Faculty, Duzce University, Duzce, Turkey

Bibliografia

• [1] Perlroth J., Choi B., Spellberg B., Nosocomial fungal infections: epidemiology, diagnosis, and treatment, Med. Mycol., 2007, 45, 321–346 http://dx.doi.org/10.1080/13693780701218689[WoS][Crossref]
• [2] Kullberg B.J., and Oude Lashof A.M., Epidemiology of opportunistic invasive mycoses, Eur. J. Med. Res., 2002, 7, 183–191
• [3] Luzzati R., Amalfitano G., Lazzarini L., Nosocomial candidemia in non-neutropenic patients at an Italian tertiary care hospital, Eur. J. Clin. Microbiol. Infect. Dis., 2000, 19, 602–607 http://dx.doi.org/10.1007/s100960000325[Crossref]
• [4] Wisplinghoff H., Bischoff T., Tallent S.M., Seifert H., Wenzel R.P., Edmond M.B., Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study, Clin. Infect. Dis., 2004, 39, 309–317 http://dx.doi.org/10.1086/421946[Crossref]
• [5] Leleu G., Aegerter P., Guidet B., Systemic candidiasis in intensive care units: a multicenter, matched-cohort study, J. Crit. Care, 2002, 17, 168–175 http://dx.doi.org/10.1053/jcrc.2002.35815[Crossref]
• [6] Wey S.B., Mori M., Pfaller M.A., Woolson R.F., Wenzel R.P., Hospital-acquired candidemia: The attributable mortality and excess length of stay, Arch. Intern. Med., 1988, 148, 2642–2645 http://dx.doi.org/10.1001/archinte.148.12.2642[Crossref]
• [7] Scheinfeld N.S., Lambiase M.C., Candidiasis, cutaneous, 2006., available in the emedicine database (http://www.emedicine.com/derm/topic67.htm)
• [8] Aragon D., Ring C.A., Covelli M., The influence of diabetes mellitus on postoperative infections, Crit. Care Nurs. Clin. North. Am., 2003, 15, 125–135 http://dx.doi.org/10.1016/S0899-5885(02)00036-9[Crossref]
• [9] Moutschen M.P., Scheen A.J., Lefebvre P.J. Impaired immune responses in diabetes mellitus: analysis of the factors and mechanisms involved. Relevance to the increased susceptibility of diabetic patients to specific infections, Diabetes Metab., 1992, 18, 187–201
• [10] Heidenreich S., Kubis T., Schmidt M., Fegeler W., Glucocorticoid-induced alterations of monocyte defense mechanisms against Candida albicans, Cell. Immunol., 1994, 157, 320–327 http://dx.doi.org/10.1006/cimm.1994.1230[Crossref]
• [11] Uzun O., Ascioglu S., Anaissie E.J., Rex J.H., Risk factors and predictors of outcome in patients with cancer and breakthrough candidemia, Clin. Infect. Dis., 2001, 32, 1713–1717 http://dx.doi.org/10.1086/320757[Crossref]
• [12] Yeast-Candida., available in the nutramed database (http://www.nutramed.com/allergy/candida.htm)
• [13] Wisplinghoff H., Bischoff T., Tallent S.M., Seifert H., Wenzel R.P., Edmond M.B., Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study, Clin. Infect. Dis., 2004, 39, 309–317 http://dx.doi.org/10.1086/421946[Crossref]
• [14] Pappas P.G., Rex J.H., Sobel J.D., Filler S.G., Dismukes W.E., Walsh T.J., et al., “Infectious Diseases Society of America: guidelines for treatment of candidiasis”, Clin. Infect. Dis., 2004, 38, 161–189 http://dx.doi.org/10.1086/380796[Crossref]
• [15] Tortorano A.M., Kibbler C., Peman J., Bernhardt H., Klingspor L., Grillot R., Candidaemia in Europe: epidemiology and resistance, Int. J. Antimicrob. Agents., 2006, 27, 359–366 http://dx.doi.org/10.1016/j.ijantimicag.2006.01.002[Crossref]
• [16] Muñoz P., Fernández-Turégano C.P., Alcalá L., Rodríguez-Créixems M., Peláez T., Bouza E., Frequency and clinical significance of bloodstream infections caused by C. albicans strains with reduced susceptibility to fluconazole, Diagn. Microbiol. Infect. Dis., 2002, 44, 163–167 http://dx.doi.org/10.1016/S0732-8893(02)00432-7[Crossref]
• [17] Maida C.M., Milici M.E., Oliveri S., In vitro activity of fluconazole, voriconazole and caspofungin against clinical yeast isolates, J. Chemother., 2007, 19, 277–82

Identyfikatory

DOI

10.2478/s11536-008-0004-3